Response-Independent Survival Benefit in Metastatic Colorectal Cancer: A Comparative Analysis of N9741 and AVF2107
Axel Grothey(Campbell Clinic), Daniel J. Sargent(National Institute of Agricultural Botany), Herbert I. Hurwitz(Duke Medical Center), R. Mass(Translational Genomics Research Institute), Richard M. Goldberg(Ontario Institute for Cancer Research), Sam Suzuki(Translational Genomics Research Institute), Somnath Sarkar(Translational Genomics Research Institute), Ramesh K. Ramanathan(Ironwood Pharmaceuticals (United States)), Eric Hedrick(Florida Hospital Cancer Institute)
Cited by 171
Related Papers
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
|New England Journal of Medicine|2015|9.4k
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Tumor Microsatellite-Instability Status as a Predictor of Benefit from Fluorouracil-Based Adjuvant Chemotherapy for Colon Cancer
|New England Journal of Medicine|2003|2.1k